Citadel Advisors’s Candel Therapeutics CADL Stock Holding History

Citadel Advisors’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$356K	Sell	72,666 -153,690	-68%	-$836K	﹤0.01%	10084
2025 Q4	$1.28M	Sell	226,356 -25,935	-10%	-$140K	﹤0.01%	6872
2025 Q3	$1.29M	Buy	+252,291	New	+$1.46M	﹤0.01%	6995
2025 Q2	–	Sell	-9,636	Closed	-$49.6K	–	12691
2025 Q1	$54.4K	Sell	9,636 -281,513	-97%	-$2.3M	﹤0.01%	12228
2024 Q4	$2.53M	Buy	291,149 +291,048	+288,166%	+$1.72M	﹤0.01%	5152
2024 Q3	$700	Buy	+101	New	+$627	﹤0.01%	13966
2024 Q1	–	Sell	-16,852	Closed	-$24.8K	–	14607
2023 Q4	$24.8K	Sell	16,852 -15,300	-48%	-$14.9K	﹤0.01%	12442
2023 Q3	$29.9K	Buy	+32,152	New	+$37.2K	﹤0.01%	12273
2023 Q2	–	Sell	-47,174	Closed	-$64.6K	–	14397
2023 Q1	$64.6K	Buy	+47,174	New	+$92K	﹤0.01%	11826
2022 Q4	–	Sell	-16,851	Closed	-$53K	–	14895
2022 Q3	$53K	Buy	+16,851	New	+$57.1K	﹤0.01%	11580

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's CADL Position: Q1 2026 in Review

Citadel Advisors reduced its Candel Therapeutics (CADL) stake by 68% in Q1 2026, selling an estimated $836K and leaving 72,666 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #10084.

Citadel Advisors first reported a position in CADL in Q3 2022 and has held it in 10 quarters since. The position peaked at $2.53M in Q4 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

Citadel Advisors held 72,666 shares of Candel Therapeutics worth $356K as of Q1 2026.
Citadel Advisors sold 153,690 Candel Therapeutics shares in Q1 2026, an estimated $836K.
Candel Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10084 holding.
Citadel Advisors first reported a position in Candel Therapeutics in Q3 2022 and has held it in 10 quarters since.
Citadel Advisors's Candel Therapeutics position peaked at $2.53M in Q4 2024.
114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.